Inclusion Criteria:

          -  Informed consent explained to, understood by and signed by patient/guardian;
             patient/guardian given copy of informed consent.

          -  3 to 17 years of age for pediatric patients, ≥18 years of age for adults; NOTE:
             children will not be allowed to enroll in a dose cohort until a minimum of 2 adult
             subjects are enrolled and complete their DLT assessment follow-up at that dose level

          -  Diagnosis of recurrent HL with a treatment plan that will include high dose
             chemotherapy with/without total body irradiation and autologous cell transplantation

          -  NHL patients with ALK negative CD30+ anaplastic large-cell lymphomas, CD30+ ALCL
             regardless of ALK status, with chemotherapy-sensitive relapse, CD30+ high-risk DLBCL,
             CD30+ cutaneous T cell lymphoma, or CD30+ mycosis fungoides who are otherwise eligible
             for transplant, are eligible for this study

          -  CD30+ disease (result can be pending at the time of cell procurement, but must be
             confirmed prior to treatment with ATLCAR.CD30 cells); NOTE: CD30 + disease is defined
             as requiring documentation of CD30 expression by immunohistochemistry based on the
             institutional hematopathology standard.

          -  Evidence of adequate organ function as defined by:

               -  The following is required prior to procurement (NOTE: labs do not need to be
                  redrawn if they have already been performed as part of SOC pre-transplant
                  work-up; Subject must be eligible to receive ASCT)

                    -  Hgb ≥ 8.0g/dL

                    -  Bilirubin ≤1.5 times the upper limit of normal (ULN)

                    -  AST ≤ 3 times ULN

                    -  Serum creatinine ≤1.5 times ULN

                    -  Cardiac and pulmonary function that is adequate for ASCT

               -  The following is required prior to infusion of ATLCAR.CD30 cells:

                    -  Absolute neutrophil count (ANC) ≥500 cells/mm^3 for 3 consecutive days;
                       Note: ANC may be measured at the beginning and the end of a time frame
                       expanding at least 3 days and does not need to be evaluated on each
                       individual day AND

                    -  Platelet count ≥25,000 cells/mm^3 without transfusion over preceding 5 days
                       Note: Platelets may be measured at the beginning and the end of a time frame
                       expanding at least 5 days and does not need to be evaluated on each
                       individual day AND

                    -  Hg ≥8g/dL without transfusion support over preceding 5 days Note: Hg may be
                       measured at the beginning and the end of a time frame expanding at least 3
                       days and does not need to be evaluated on each individual day

                    -  Bilirubin ≤1.5 times the upper limit of normal (ULN)

                    -  AST ≤ 3 times ULN

                    -  Serum creatinine ≤1.5 times ULN

                    -  Pulse oximetry of > 90% on room air

          -  Imaging results from within 60 days prior to transplant (used as baseline measure for
             documentation of disease status). Note: Results may be obtained at a time point
             greater than 30 days from transplant if obtained per the patient's standard of care
             and with prior sponsor approval.

          -  Negative serum pregnancy test within 72 hours prior to procurement and again 72 hours
             prior to infusion

          -  Karnofsky or Lansky score of > 60%

          -  Considered at high risk for relapse as defined by: The presence of ≥ 1 of the
             following: failure to achieve CR post initial treatment; relapsed disease with an
             initial remission duration of <12 months; or extranodal involvement at the start of
             pre-transplant salvage therapy

          -  Subjects must have autologous transduced activated T cells that meet the Certificate
             of Analysis (CoA) acceptance criteria

          -  Women of childbearing potential (WOCBP) should be willing to use 2 methods of birth
             control or be surgically sterile, or abstain from heterosexual activity for the course
             of the study, and for 6 months after the study is concluded. WOCBP are those who have
             not been surgically sterilized or have not been free from menses for > 1 year. The two
             birth control methods can be composed of: two barrier methods or a barrier method plus
             a hormonal method to prevent pregnancy. The male partner of WOCBP subjects enrolled
             into the trial should be instructed to use a condom by their female partner enrolled
             in the trial.

        Exclusion Criteria:

          -  Received any investigational agents or received any tumor vaccines within the previous
             six weeks prior to cell infusion.

          -  Received anti-CD30 antibody-based therapy within the previous 4 weeks prior to cell
             infusion

          -  History of hypersensitivity reactions to murine protein-containing products

          -  Pregnant or lactating

          -  Tumor in a location where enlargement could cause airway obstruction.

          -  Current use of systemic corticosteroids at doses ≥10mg/day prednisone or its
             equivalent; those receiving <10mg/day may be enrolled at discretion of investigator

          -  Active infection with HIV, HTLV, HBV, HCV (can be pending at the time of cell
             procurement; only those samples confirming lack of active infection will be used to
             generate transduced cells) . Active infection is defined as not being well controlled
             on therapy (Note: To meet eligibility subjects are required to be negative for HIV
             antibody or HIV viral load, negative for HTLV1 and 2 antibody, negative for Hepatitis
             B surface antigen, or negative for HCV antibody or HCV viral load).